The prospective German NICO study provides vital real-world insights into melanoma brain metastasis treatment. This study evaluated the effectiveness and safety of nivolumab combined with ipilimumab versus nivolumab monotherapy in a large cohort of 755 patients. Importantly, the research includes patients often excluded from clinical trials, offering a realistic view of oncology practice. Consequently, the findings help clinicians understand how these immunotherapies perform in diverse patient populations, including those with challenging prognostic factors.

During the study, researchers observed that a significant proportion of patients achieved meaningful clinical benefits. Specifically, first-line treatment with the nivolumab and ipilimumab combination resulted in an objective response rate (ORR) of 46.2% in patients with brain involvement. In contrast, those receiving nivolumab alone in the first-line setting showed an ORR of 61.5%. Furthermore, the 3-year overall survival (OS) rates for the combination group reached 34%, while the monotherapy group reached 42.7%. These variations likely reflect baseline differences, as the combination group often included younger patients with more aggressive disease markers.

Optimizing Melanoma Brain Metastasis Treatment for Asymptomatic Patients

Notably, the presence of symptoms and the use of steroids significantly impacted patient outcomes. For instance, patients with asymptomatic brain metastases showed a 3-year OS rate of 42.2%. However, those with symptomatic disease requiring dexamethasone saw this rate drop to 20%. Therefore, early detection and treatment before the onset of neurologic symptoms remain critical goals in management. Moreover, a landmark analysis at three months showed that patients achieving a complete or partial response enjoyed excellent long-term survival. Specifically, responders on nivolumab alone achieved an 89.6% 3-year OS rate, while those on the combination reached 71.9%.

Safety monitoring during the NICO study confirmed that the adverse event profile remained manageable. Overall, the rates of serious grade 3 or 4 treatment-related adverse events did not differ substantially between patients with or without brain metastases. Health-related quality of life (HRQoL) remained stable throughout the treatment duration for most participants. Consequently, this study reinforces the feasibility of using dual-agent or single-agent immunotherapy in real-world settings. These results suggest that many patients can derive long-term survival benefits without compromising their quality of life.

Frequently Asked Questions

How does nivolumab monotherapy compare to the combination for brain metastases?

In this real-world setting, both options showed activity. While clinical trials often favor the combination, this study noted that nivolumab alone provided high response rates in certain patient subgroups, though baseline characteristics between groups differed significantly.

Does the use of steroids affect immunotherapy outcomes?

Yes. Patients using dexamethasone for symptomatic brain metastases generally had lower survival rates compared to asymptomatic patients. This highlights the importance of managing brain disease before symptoms require high-dose corticosteroids.

Is the safety profile different for patients with brain metastases?

According to the NICO study, there were no substantial differences in the rates of serious adverse events based on the presence of brain metastases, suggesting the treatments are equally tolerable in this population.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Gutzmer R et al. Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study. Int J Cancer. 2026 Mar 15. doi: 10.1002/ijc.70440. PMID: 41833546.

Tawbi HA et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379:722-730.

Long GV et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672-681.